Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
Clinical trial NCT03505099 · COMPLETED
Trial details
- NCT number
- NCT03505099
- Sponsor
- Novartis Gene Therapies
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-02
- Primary completion
- 2021-06-15
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.